Materiality of Superbugs
Date
24 November 2020
The viewpoint covers:
Why antimicrobial resistance (AMR) is a material issue for investors in pharmaceutical companies.
The main risks and opportunities presented by superbugs for pharma companies.
Resources available for investors to navigate through these risks and steer better outcomes.
How the Access to Medicine Foundation supports investor leadership in the fight against superbugs through the Investor Action on AMR initiative.
The issues were discussed in a virtual event organised by the Investor Action on AMR Initiative, which is jointly coordinated by the Access to Medicine Foundation, the FAIRR Initiative, the UK Department of Health & Social Care, and the Principles for Responsible Investment (PRI). Watch the event here. Â